Search results

Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for

Globus Medical, Inc. GMED used its second-quarter 2026 call to emphasize margin execution and continued spine share gains, while management flagged Nevro and Enabling Technologies as risks within

Tyson Foods, Inc. TSN entered the final stretch of fiscal 2026 with a sharper split across its portfolio. Chicken and Prepared Foods remained productive, but worsening Beef economics pressured

Astec Industries, Inc. ASTE presents a split investment picture. Its valuation sits below key historical and industry benchmarks, while infrastructure demand, backlog growth and a larger aftermarket

Diversified Energy Company DEC used its second-quarter 2026 earnings call to frame operated drilling as an extension of its acquisition-and-optimization model, not a strategic pivot. Management said

Revolve Group, Inc. RVLV beat second-quarter earnings expectations as sales growth stayed broad and underlying merchandising economics improved. Yet tariff refunds amplified reported profitability

SoundHound AI, Inc. SOUN shares have lost 16.9% in the past three months even as second-quarter revenues, enterprise adoption and operating metrics improved. That split between price action and

Cardinal Health CAH is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open.

The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1%

ConocoPhillips COP used its second-quarter 2026 earnings call to reinforce a $7 billion free-cash-flow inflection by 2029, with lower capital spending and higher cash flow from major projects